LHLing He

Ling He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling He has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Network Pharmacology and Bioinformatic Prediction of Five Medicinal-Food Homologous Plants Against the Progression from Chronic Atrophic Gastritis to Gastric Cancer

    by Menglin Chen, Houshu Tu, Chengming Yang, Cui Xu, Yaqian Huang, Ling He

    Chronic atrophic gastritis (CAG) progresses through distinct pathological stages to gastric cancer. This computational study employed network pharmacology and bioinformatics to predict the active compounds, targets, and pathways of five medicinal-food homologous plants ( Houttuyniae Herba , Mume Fructus , Rhizoma Dioscoreae , Portulacae Herba , and Curcumae longae Rhizoma ) against this progression. We identified 28 active compounds and 242 targets from TCMSP. differentially expressed genes from GSE130823 and GSE55696 were integrated with weighted gene co-expression network analysis, yielding 129 candidate targets. Machine learning (LASSO and random forest) prioritized AR , EIF6 , GSTM2 , and FOSB as potential diagnostic biomarkers distinguishing CAG from cancer. Enrichment analysis predicted involvement of IL-17, TNF, and p53 pathways. Compound-target-pathway network analysis identified quercetin and kaempferol as multi-target compounds. Molecular docking predicted binding affinities ranging from weak-to-moderate for core genes (−2.60 to −5.83 kcal/mol) and moderate-to-strong for inflammatory targets (up to −7.25 kcal/mol for quercetin-TNF). These findings computationally predict candidate mechanisms of these five plants, offering a rationale for future experimental validation and therapeutic development.

  • Open Access

    Mapping mitochondria-associated research in inflammatory bowel disease

    by Houshu Tu, Menglin Chen, Panpan Zhu, Jing Hong, Ling He

    Background: Mitochondria-associated research has become increasingly prominent in inflammatory bowel disease (IBD), but its publication growth, collaboration structure, knowledge base, and thematic evolution have not been comprehensively quantified. Methods: Web of Science Core Collection records published from 2010 through 2025 were retrieved on September 19, 2025. Of 215 candidate records, 112 met prespecified eligibility criteria. The 111 records with complete Full Record and Cited References metadata were used for primary analyses; 1 additional eligible record was included only in an annual-output sensitivity analysis. Bibliometrix/Biblioshiny, VOSviewer 1.6.20, and R were used for descriptive, network, temporal, and robustness analyses. Results: Annual output increased significantly (Kendall τ = 0.638, P = .0009; Sen slope = 1.20 publications/year, 95% confidence interval 0.50–1.71), whereas annualized citation impact showed no significant monotonic trend after exclusion of 2025 (Spearman ρ = 0.093, P = .742). China led corresponding-author output (39 articles), while the United States had the highest aggregate citation count (985). Multi-country publications accounted for 35 of 111 articles (31.5%). The largest institutional collaboration component contained 53 organizations in 8 clusters, and the author component contained 15 authors in 2 clusters. The primary author-keyword network included 22 terms, 6 clusters, 90 links, and a total link strength of 181. Mitophagy, mitochondrial dynamics, and machine learning were positioned toward the recent end of the temporal spectrum. Cited-source and cited-reference networks were densely interconnected, indicating a shared multidisciplinary knowledge base. Conclusion: Mitochondria-associated IBD research expanded substantially during 2010 to 2025, with concentrated geographic leadership, recurrent but uneven international collaboration, and overlapping themes spanning inflammation, epithelial biology, metabolism, mitochondrial quality control, and host–microbiome interactions. The findings provide a reproducible map of the literature but should not be interpreted as evidence of biological causality or discrete mechanistic pathways.

  • Open Access

    From histological recovery to residual gastric cancer risk after Helicobacter pylori eradication: a multi-database bibliometric and clinical decision-domain analysis

    by Houshu Tu, Menglin Chen, Panpan Zhu, Jing Hong, Ling He

    Background: Successful Helicobacter pylori eradication reduces gastric cancer risk, but residual risk persists in patients with established atrophy or intestinal metaplasia. We integrated multi-database science mapping with independent article-level clinical decision-domain classification to quantify how the research agenda evolved from mucosal recovery to residual-risk management and to identify decision-critical evidence gaps. Methods: Web of Science, Scopus, and PubMed were searched through 27 July 2026. Records were deterministically deduplicated and independently screened. Bibliometric networks, thematic structure, temporal bursts, and cited-reference relationships were analyzed. Two reviewers independently classified each publication into one of five mutually exclusive clinical decision domains. Temporal distributions were compared using Pearson's chi-square test, and a research-priority framework was synthesized by triangulating the quantitative findings with representative clinical evidence. Results: Of 778 source records, 283 publications from 1993 to 2026 were included. Reviewer agreement was 78.80% (Cohen's kappa = 0.722). Histological regression and mucosal recovery predominated in 1993–2007 (34.7%), whereas surveillance and prevention (39.6%) and risk stratification (30.2%) became dominant in 2008–2017 and remained the leading domains in 2018–2026. Domain distributions differed significantly across periods ( P = 0.008) and remained significant after exclusion of the incomplete 2026 publication year. The principal translational gaps were the absence of externally validated multimodal risk thresholds and comparative evidence defining surveillance eligibility, intervals, duration, and outcomes. Conclusion: The field has shifted from asking whether gastric mucosal damage can recover to determining who remains at risk and how that risk should be managed. The resulting clinical decision taxonomy and research-priority framework support future validation of multimodal risk thresholds and comparative surveillance strategies; they do not establish universal surveillance or specific intervals.

  • LIMK1 and PKM as Integratively Identified Transcriptomic Signatures in Inflammatory Bowel Disease

    by Houshu Tu, Menglin Chen, Panpan Zhu, Ling He, Jing Hong

    Inflammatory bowel disease (IBD) involves complex immunometabolic dysregulation. Mitochondria-associated endoplasmic reticulum membranes (MAMs) link metabolic adaptation and inflammatory signaling, but gene expression features associated with MAM-related transcriptomic states in IBD remain unclear. Public transcriptomic datasets were integrated with a curated MAM-related gene set and herbal target information. Differential expression analysis, weighted gene coexpression network analysis, and machine learning-assisted feature selection were used to identify candidate genes. A two-gene nomogram was constructed and evaluated in discovery and independent validation datasets. Functional enrichment, immune deconvolution, regulatory network prediction, molecular docking, 200-ns molecular dynamics simulations, and preliminary quantitative polymerase chain reaction validation were performed. LIMK1 and PKM were identified as candidate transcriptomic signature genes associated with IBD status and MAM-related transcriptional states, showing discriminatory performance in independent datasets. Both genes were associated with cytokine–cytokine receptor interaction and drug metabolism–cytochrome P450 pathways and were linked to macrophage-related immune states. Structural analyses suggested stable predicted binding between PKM and 1-(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol and structurally plausible interactions between LIMK1 and palmatine. Preliminary tissue-level validation supported the disease-associated expression pattern of PKM , whereas LIMK1 showed a consistent but nonsignificant upward trend. LIMK1 and PKM may represent candidate transcriptomic signatures associated with MAM-related regulatory states in IBD. These findings should be interpreted as hypothesis-generating associations rather than evidence of MAM localization, functional causality, or therapeutic efficacy. Further protein-level and functional validation is required.

  • Open Access

    Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: Clinical, pharmacogenetic, and microbiome perspectives

    by Hou-Shu Tu, Meng-Lin Chen, Jing Hong, Ling He

    Helicobacter pylori infection remains a major global health challenge, contributing to chronic gastritis, peptic ulcer disease, and gastric cancer. Rising antimicrobial resistance, host genetic variability, and inconsistent patient adherence have limited the effectiveness of conventional proton pump inhibitor-based eradication regimens. Vonoprazan-amoxicillin (VPZ-AMO) dual therapy is a promising first-line alternative, with high eradication rates, favorable tolerability, and simplified antibiotic exposure demonstrated in multicenter trials across Asia. Evidence suggests that VPZ-AMO dual therapy may outperform traditional proton pump inhibitor-based triple or bismuth quadruple therapies, particularly in populations with high clarithromycin resistance. However, important questions remain regarding its generalizability, optimal dosing, host pharmacogenetic effects, and potential long-term impacts on the gut microbiota. This opinion review summarizes current clinical evidence, highlights unresolved controversies, and outlines future research priorities, including multicenter validation, host factor-guided therapy, microbiome monitoring, and dosing optimization. By integrating these elements into a structured, sequential framework, VPZ-AMO dual therapy is presented as a safe, effective, and adaptable regimen, with substantial potential to improve Helicobacter pylori management and reduce the global burden of associated gastrointestinal diseases.

  • Open Access

    Bioinformatic identification of CD8+ T cell activation mediated by key genes in fecal microbiota transplantation for irritable bowel syndrome

    by Ying Fei, Ming-Yi Gao, Nan Qiao, Jia Hu, Ling He, Jiao-Li Zhou, Ning-Ning Zheng, Ting-Ting Liu

    Background: The effect of fecal microbiota transplantation (FMT) in treating irritable bowel syndrome (IBS) may be attributed to the modulation of CD8 + T cells. This study aims to identify FMT-mediated key genes to explore the underlying mechanism. Methods: Transcriptomic datasets GSE138297 (colonic biopsies from 8 IBS patients pre- and post-FMT) and GSE134649 (single-cell data from 3 healthy colon tissues) were obtained from GEO during December 2023–December 2024. Key genes were identified by intersecting differentially expressed genes (DEGs) and the most relevant co-expression module derived from weighted correlation network analysis. Functional enrichment, gene set enrichment analysis, immune infiltration profiling via TIMER 2.0, single-cell annotation using PanglaoDB and Seurat, and drug–gene interaction screening from DrugBank were conducted to decipher the regulatory mechanisms. Results: Ten key genes were identified through integration of DEGs and the MEgreen module. Functional analyses revealed significant involvement in the positive regulation of CD8 + T cells activation. Immune infiltration assessment demonstrated a marked increase in CD8 + T cells abundance post-FMT. Single-cell data indicated predominant expression of LILRB1, P2RY13, CLEC10A, and CLEC12A in dendritic cells, and LILRB1, PIPOX, and CLEC11A were annotated within CD8 + T cells clusters in healthy colonic tissue. Nine (database-derived and speculative) drugs targeting seven key genes were identified, most implicated in the management of IBS symptoms or immunomodulation. Conclusion: An association between key gene regulation and CD8 + T cell-related immunoregulation is correlated with the therapeutic effect of FMT in IBS.

  • Open Access

    Beyond weight loss: Quality of life and internalized weight bias in endoscopic bariatric revision

    by Hou-Shu Tu, Meng-Lin Chen, Jing Hong, Ling He

    We commend Agrawal et al for their insightful and pioneering study, which provides new evidence that revisional endoscopic bariatric therapy (EBT) can significantly improve quality of life and reduce internalized weight bias. Their work rightly demonstrates that these procedures provide benefit beyond weight loss alone. To build on these findings, we suggest that future studies should address certain remaining methodological issues. These include recruiting larger and more heterogeneous cohorts to assess generalizability, using multivariable analysis to control for the confounding effects of anti-obesity medications, and implementing longitudinal assessments to determine the duration of improvements in patient-reported outcomes. Establishing a causal link between early improvements in EBT and internalized weight bias with long-term weight control will be vital to establish the therapeutic value of revisional EBT as part of a comprehensive and multi-modal treatment for obesity.

  • Open Access

    FSTL1 is a prognostic marker and promotes invasion and metastasis of colon cancer

    by Chao Zhong, Zhaorui Cheng, Yuansen Shu, Xiaojuan Yang, Jia Hu, Ling He, Xiushen Li, Xu Xiang Chen, Yun Liu

    Background Colorectal cancer (CRC) stands as the most common gastrointestinal malignancy, with the Follistatin-like 1 (FSTL1) gene associated with unfavorable outcomes in diverse cancer forms. Nonetheless, the precise mechanisms through which FSTL1 influences CRC pathogenesis and its associated multi-omics characteristics remain unclear. Methods This study leveraged RNA sequencing and single-cell RNA sequencing (scRNAseq) data from the Gene Expression Omnibus (GEO) database to scrutinize the expression profile, prognostic significance, and clinicopathological relevance of FSTL1 in colorectal cancer. Gene set enrichment analysis (GSEA) and protein-protein interaction (PPI) network analysis were conducted to delve into the potential biological functions of FSTL1 in colorectal cancer and its associated pathways. The ESTIM algorithm and Tumor Immune Estimation Resource (TIDE) database were utilized to investigate FSTL1 expression in immune cell infiltration and immune checkpoints. Mutation characteristics of FSTL1 were elucidated using the cBioPortal database. The pRRophetic package was employed to identify potential chemotherapeutic drugs targeting FSTL1. Expression levels of FSTL1 in colon cancer and adjacent normal tissues were evaluated using the Human Protein Atlas (HPA) database. Furthermore, single-cell sequencing technology and cell communication were employed to assess the immunogenomic features of FSTL1 in the tumor microenvironment. In vitro experiments were conducted to validate the efficacy of FSTL1. Results FSTL1 levels were markedly higher in colorectal cancer tissues compared to healthy tissues, correlating significantly with unfavorable patient outcomes. Elevated FSTL1 expression was closely linked to key biological processes including the PI3K pathway, cell adhesion, proliferation, migration, and extracellular matrix remodeling. Furthermore, FSTL1 expression exhibited strong associations with immune cell levels and the tumor immune microenvironment in colorectal cancer. Notably, FSTL1 mutations predominantly comprised missense mutations and displayed significant correlations with various immune checkpoints and low methylation levels. Axitinib emerged as a promising targeted therapeutic option for patients with high FSTL1 expression. Analysis from the HPA database confirmed elevated FSTL1 expression in colorectal tissues compared to adjacent normal tissues. Single-cell sequencing analysis identified stromal cells as the primary source of abundant FSTL1 expression, potentially influencing tumor microenvironment remodeling by myeloid and B cells via the APP-CD74 pathway. Downregulating FSTL1 expression in colon cancer cells suppresses the proliferation, motility, and invasiveness of SW480 and HCT116 colon cancer cells. Conclusion In summary, the findings of the study indicate that elevated FSTL1 expression could serve as a prognostic biomarker for unfavorable outcomes in colorectal cancer (CRC) diagnosis and may also identify potential targets for immunotherapy in CRC.


  • Open Access

    The Causal Correlation Between Gastroesophageal Reflux Disease and Chronic Widespread Pain: A Bidirectional Mendelian Randomization Study

    by Menglin Chen, Houshu Tu, Jiaoli Zhou, Yi Zhang, Shuting Wen, Yao Xiao, Ling He

    Background: Previous observational research found a relationship between gastroesophageal reflux disease (GERD) and chronic widespread pain (CWP). Despite this, it is unknown which, if any, of the conditions produces the other. Our study will use bidirectional Mendelian randomization (MR) to evaluate their causal link. Methods: We examined two sets of publically accessible data from genome-wide association studies (GWAS): GERD (129,080 cases and 602,604 controls) and CWP (6,914 cases and 242,929 controls). We used the inverse variance weighting (IVW) approach as the major analysis method, but we also ran weighted median and MR-Egger regression analyses. We performed various sensitivity studies to assess the conclusions’ consistency, horizontal pleiotropy, and stability. Results: MR analysis showed that CWP increased the risk of developing GERD [NSNP = 4, odds ratio (OR): 245.244; 95% confidence interval (CI): 4.35E+00,1.38E+04; p =0.007 < 0.05] and vice versa (NSNP = 28; OR:1.019; 95% CI: 1.009– 1.029; p = 0.029 < 0.05). Bidirectional evidence of causality existed. The sensitivity analysis demonstrated the robustness and reliability of the findings. Conclusion: Our study demonstrated a bidirectional causal relationship between GERD and chronic widespread pain, and future interventions for CWP may be an effective strategy for preventing or mitigating GERD and vice versa.